The estimated Net Worth of Kevin F. Hanley is at least $169 Tisíc dollars as of 14 December 2018. Kevin Hanley owns over 10,000 units of Ocular Therapeutix Inc stock worth over $168,800 and over the last 7 years Kevin sold OCUL stock worth over $0.
Sign up
Kevin Hanley OCUL stock SEC Form 4 insiders trading
Kevin has made over 2 trades of the Ocular Therapeutix Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Kevin bought 10,000 units of OCUL stock worth $55,000 on 14 December 2018.
The largest trade Kevin's ever made was buying 10,000 units of Ocular Therapeutix Inc stock on 14 December 2018 worth over $55,000. On average, Kevin trades about 5,000 units every 1 days since 2018. As of 14 December 2018 Kevin still owns at least 20,000 units of Ocular Therapeutix Inc stock.
You can see the complete history of Kevin Hanley stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Kevin Hanley's mailing address?
Kevin's mailing address filed with the SEC is C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD, MA, 01730.
Insiders trading at Ocular Therapeutix Inc
Over the last 10 years, insiders at Ocular Therapeutix Inc have traded over $73,512,800 worth of Ocular Therapeutix Inc stock and bought 6,361,550 units worth $38,632,070 . The most active insiders traders include Management Inc. Opaleye, Road Llc Summer a Venture Management Co. V, L.... On average, Ocular Therapeutix Inc executives and independent directors trade stock every 43 days with the average trade being worth of $999,228. The most recent stock trade was executed by Sanjay Nayak on 23 August 2024, trading 1,832 units of OCUL stock currently worth $16,525.
What does Ocular Therapeutix Inc do?
ocular therapeutix, inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel-based formulation technology. ocular therapeutix’s lead product candidate, dextenza™ (dexamethasone insert) 0.4 mg for intracanalicular use, has completed phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. otx-tp (travoprost insert) is in phase 3 clinical development for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension. the company’s earlier stage assets include otx-tic, a sustained release travoprost intracameral injection for the reduction in intraocular pressure in patients with glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. these injections include the development of otx-tki, a tyrosine kinase inhib
What does Ocular Therapeutix Inc's logo look like?
Complete history of Kevin Hanley stock trades at Ocular Therapeutix Inc
Ocular Therapeutix Inc executives and stock owners
Ocular Therapeutix Inc executives and other stock owners filed with the SEC include:
-
Antony Mattessich,
President, Chief Executive Officer, Director -
Patricia Kitchen,
Chief Operations Officer -
Antony Mattessich,
Pres, CEO & Director -
Michael Goldstein,
Chief Medical Officer -
Donald Notman,
Chief Financial Officer -
Dr. Michael H. Goldstein M.M., M.D., M.B.A.,
Pres of Ophthalmology & Chief Medical Officer -
Patricia Kitchen,
Chief Operating Officer -
Philip C. Strassburger,
Gen. Counsel -
Leslie Williams,
Independent Director -
Charles Warden,
Independent Chairman of the Board -
Suh Hong Seung,
Independent Director -
Bruce Peacock,
Independent Director -
Richard Lindstrom,
Independent Director -
Jeffrey Heier,
Independent Director -
Christopher Brinzey,
Managing Director -
Christopher White,
Senior Vice President, Head of Business and Corporate Development -
Dr. Rabia Gurses Ozden,
Sr. VP of Clinical Devel. -
Scott Corning,
Sr. VP of Commercial -
Tracy Smith,
VP of HR -
Christopher G. White,
Chief Bus. Officer -
William H. Ransone II,
VP of Global Sales & Marketing -
Dr. Peter K. Jarrett Ph.D.,
Chief Scientific Officer -
Donald Notman Jr.,
Chief Financial Officer -
Jaswinder Chadha,
Director -
Jonathan H. Talamo,
Chief Medical Officer -
Charles Andrew Hurley,
Chief Commercial Officer -
James M Garvey,
Director -
James Fortune,
Chief Operating Officer -
Amarpreet Sawhney,
President and CEO -
William J Oshea,
Director -
Eric Ankerud,
See Remarks -
W Bradford Smith,
CFO and Treasurer -
Pravin Dugel,
See Remarks -
Rabia Gurses Ozden,
Chief Medical Officer -
Daniel M Bollag,
Sr. VP Reg. Affairs & Quality -
Kevin F. Hanley,
Sr. VP Technical Operations -
Management Inc. Opaleye,
-
Venture Management Co. V, L...,
-
Ii, L.P.Ascension Health Ve...,
-
Iv, Llcsv Life Sciences Fun...,
-
Venture Capital Iii, L.P.Ve...,
-
Iv, Llcsv Life Sciences Fun...,
-
Road Llc Summer,
-
Merilee Raines,
Director -
Philip C. Strassburger,
General Counsel -
Sanjay Nayak,
Chief Strategy Officer -
Nadia Waheed,
Chief Medical Officer